Clinical Laserthermia Systems

The current patent for CLS non-cooled laser applicators is valid until 2036 and has its origins in a collaboration that CLS initiated in 2010 with the German laser technology company Laser- und Medizin-Technologie GmbH, LMTB, regarding fiber development. In 2017, CLS purchased parts of LMTB and secured access to LMTB's patents and know-how for the unique diffuser technology. CLS diffuser-type laser applicator makes it possible to treat larger cancer tumors, without cooling the laser applicator like our competitors, and is part of the company's extensive portfolio of laser applicators and instruments that, together with the mobile laser unit and MRI thermometry software, form the core of CLS's technology platform.

The new patent application is an important part of the work to create and protect CLS's intellectual property rights, which are valuable assets in the company. Based on new knowledge from our clinical activities in the US and at Skåne University Hospital, the CLS non-cooled laser applicator has been improved through new inventions that CLS believes are patentable. If the patent application is approved, protection is provided for the new inventions until 2044.

"We are following our patent strategy and continue to build value in the company. Feedback from our customers and clinical use confirm that we have a unique basic technology with great benefits for users and patients. The patent application is based on market feedback and continued research and development, and contains several improvements, The application aims to further strengthen and significantly extend our patent protection for CLS's technology platform", says Dan Mogren, CEO, CLS.

For more information, please contact:

Dan J. Mogren, VD, Clinical Laserthermia Systems AB (publ)

Phone: +46 (0) 70-590 11 40

Email:dan.mogren@clinicallaser.com

About CLS

Clinical Laserthermia Systems AB (publ) develops and sells TRANBERG®|Thermal Therapy System, including Thermoguide Workstation and sterile disposables, for minimally invasive treatment of cancerous tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. The products are marketed for image-guided laser ablation and are used in studies for treatment with imILT®, the Company's interstitial laser thermotherapy for immunostimulatory ablation with potential abscopal effects. CLS is headquartered in Lund, Sweden, and has subsidiaries in Germany, the USA and Singapore. CLS is listed on Nasdaq First North Growth Market under the ticker CLS B. Certified Advisor (CA) is FNCA Sweden AB.

For more information about CLS, please visit the company's website: www.clinicallaser.se